MedTrace Logo

Attenuation Of Hemodynamic Response To Laryngoscopy. Role Of Dexmedetomidine. A Dose Finding Study

NCT05909215 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2023-06-18

No results posted yet for this study

Summary

Two doses of Dexmedetomidine (0.5 µ/kg and 0.75 µ/kg) will be used to attenuate the stress response to laryngoscopy in American Society of Anesthesiology, physical class I patients which will be compared with the placebo-controlled group.

Conditions

  • Hemodynamic Instability
  • Tracheal Intubation
  • Dexmedetomidine

Interventions

DRUG

Normal saline

Normal saline 20mL will be given intravenously through a syringe pump over 10 minutes

DRUG

Dexmedetomidine 0.5 microgram/kg

Dexmedetomidine 0.5 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes

DRUG

Dexmedetomidine 0.75 microgram/kg

Dexmedetomidine 0.75 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes

Sponsors & Collaborators

  • Sindh Institute of Urology and Transplantation

    lead OTHER

Principal Investigators

  • Syed M Abbas · Associate Professor Dept of Anaesthesia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-23
Primary Completion
2021-12-13
Completion
2021-12-13
FDA Drug
Yes

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05909215 on ClinicalTrials.gov